ID   PLD4_MOUSE              Reviewed;         503 AA.
AC   Q8BG07; Q3TD59; Q3UA19; Q6PDR0; Q8BR69;
DT   20-MAR-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 1.
DT   18-JUN-2025, entry version 155.
DE   RecName: Full=5'-3' exonuclease PLD4 {ECO:0000305|PubMed:30111894};
DE            EC=3.1.16.1 {ECO:0000269|PubMed:30111894};
DE   AltName: Full=(S,S)-bis(monoacylglycero)phosphate synthase PLD4 {ECO:0000305|PubMed:39423811};
DE            EC=3.1.4.- {ECO:0000269|PubMed:39423811};
DE   AltName: Full=Phospholipase D family member 4;
DE   AltName: Full=Phospholipase D4;
GN   Name=Pld4 {ECO:0000303|PubMed:30111894, ECO:0000312|MGI:MGI:2144765};
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   STRAIN=C57BL/6J, and NOD;
RC   TISSUE=Bone marrow, Corpora quadrigemina, Hypothalamus, and Thymus;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=FVB/N-3; TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Lung, and Spleen;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [4]
RP   DEVELOPMENTAL STAGE, SUBCELLULAR LOCATION, GLYCOSYLATION, LACK OF
RP   PHOSPHOLIPASE ACTIVITY, AND TISSUE SPECIFICITY.
RX   PubMed=21085684; DOI=10.1371/journal.pone.0013932;
RA   Yoshikawa F., Banno Y., Otani Y., Yamaguchi Y., Nagakura-Takagi Y.,
RA   Morita N., Sato Y., Saruta C., Nishibe H., Sadakata T., Shinoda Y.,
RA   Hayashi K., Mishima Y., Baba H., Furuichi T.;
RT   "Phospholipase D family member 4, a transmembrane glycoprotein with no
RT   phospholipase D activity, expression in spleen and early postnatal
RT   microglia.";
RL   PLoS ONE 5:E13932-E13932(2010).
RN   [5]
RP   SUBCELLULAR LOCATION, INDUCTION, FUNCTION, AND GLYCOSYLATION.
RX   PubMed=22102906; DOI=10.1371/journal.pone.0027544;
RA   Otani Y., Yamaguchi Y., Sato Y., Furuichi T., Ikenaka K., Kitani H.,
RA   Baba H.;
RT   "PLD4 is involved in phagocytosis of microglia: expression and localization
RT   changes of PLD4 are correlated with activation state of microglia.";
RL   PLoS ONE 6:E27544-E27544(2011).
RN   [6]
RP   DISRUPTION PHENOTYPE, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=30111894; DOI=10.1038/s41590-018-0179-y;
RA   Gavin A.L., Huang D., Huber C., Maartensson A., Tardif V., Skog P.D.,
RA   Blane T.R., Thinnes T.C., Osborn K., Chong H.S., Kargaran F., Kimm P.,
RA   Zeitjian A., Sielski R.L., Briggs M., Schulz S.R., Zarpellon A.,
RA   Cravatt B., Pang E.S., Teijaro J., de la Torre J.C., O'Keeffe M.,
RA   Hochrein H., Damme M., Teyton L., Lawson B.R., Nemazee D.;
RT   "PLD3 and PLD4 are single-stranded acid exonucleases that regulate
RT   endosomal nucleic-acid sensing.";
RL   Nat. Immunol. 19:942-953(2018).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND DISRUPTION
RP   PHENOTYPE.
RX   PubMed=34620855; DOI=10.1038/s41467-021-26150-w;
RA   Gavin A.L., Huang D., Blane T.R., Thinnes T.C., Murakami Y., Fukui R.,
RA   Miyake K., Nemazee D.;
RT   "Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory
RT   triggering by multiple sensors.";
RL   Nat. Commun. 12:5874-5874(2021).
RN   [8]
RP   FUNCTION.
RX   PubMed=39423811; DOI=10.1016/j.cell.2024.09.036;
RA   Singh S., Dransfeld U.E., Ambaw Y.A., Lopez-Scarim J., Farese R.V. Jr.,
RA   Walther T.C.;
RT   "PLD3 and PLD4 synthesize S,S-BMP, a key phospholipid enabling lipid
RT   degradation in lysosomes.";
RL   Cell 0:0-0(2024).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=38537643; DOI=10.1016/j.str.2024.02.019;
RA   Yuan M., Peng L., Huang D., Gavin A., Luan F., Tran J., Feng Z., Zhu X.,
RA   Matteson J., Wilson I.A., Nemazee D.;
RT   "Structural and mechanistic insights into disease-associated endolysosomal
RT   exonucleases PLD3 and PLD4.";
RL   Structure 32:766-779.e7(2024).
CC   -!- FUNCTION: 5'->3' exonuclease that hydrolyzes the phosphodiester bond of
CC       single-stranded DNA (ssDNA) and RNA molecules to form nucleoside 3'-
CC       monophosphates and 5'-end 5'-hydroxy deoxyribonucleotide/ribonucleotide
CC       fragments. Partially redundant with PLD4, can cleave all four
CC       nucleotides displaying higher efficiency for ssDNA and RNA fragments
CC       initiated with uridine and guanosine residues and lower efficiency for
CC       cytidine-initiated substrates. As a result, it does not always degrade
CC       polynucleotides to the single nucleotide level, it can stall at
CC       specific sites sparing certain fragments from exonucleolytic
CC       degradation (PubMed:30111894, PubMed:34620855, PubMed:38537643).
CC       Processes self and pathogenic ssDNA and RNA molecules that reach the
CC       endolysosomal compartment via phagocytosis or autophagy and may serve
CC       as 'danger' signals for recognition by innate immune receptors such as
CC       toll-like receptors (TLRs). Degrades mitochondrial CpG-rich ssDNA
CC       fragments to prevent TLR9 activation and autoinflammatory response, but
CC       it can cleave viral RNA to generate ligands for TLR7 activation and
CC       initiate antiviral immune responses. In plasmacytoid dendritic cells,
CC       it cooperates with endonuclease RNASET2 to release 2',3'-cyclic
CC       guanosine monophosphate (2',3'-cGMP), a potent stimulatory ligand for
CC       TLR7 (PubMed:34620855). Produces 2',3'-cGMPs and cytidine-rich RNA
CC       fragments that occupy TLR7 ligand-binding pockets and trigger a
CC       signaling-competent state. Can exert polynucleotide phosphatase
CC       activity toward 5'-phosphorylated ssDNA substrates although at a slow
CC       rate (PubMed:38537643). Transphosphatidylase that catalyzes the
CC       exchange with R to S stereo-inversion of the glycerol moiety between
CC       (S,R)-lysophosphatidylglycerol (LPG) and monoacylglycerol (MAG)
CC       substrates to yield (S,S)-bis(monoacylglycero)phosphate (BMP)
CC       (PubMed:39423811). Can synthesize a variety of (S,S)-BMPs representing
CC       the main phospholipid constituent of lysosomal intralumenal vesicle
CC       (ILV) membranes that bind acid hydrolases for lipid degradation
CC       (PubMed:39423811). Regulates the homeostasis and interorganellar
CC       communication of the endolysosomal system with an overall impact on
CC       cellular removal of dysfunctional organelles via autophagy as well as
CC       proper protein and lipid turnover. May play a role in myotube formation
CC       in response to ER stress (By similarity).
CC       {ECO:0000250|UniProtKB:Q8IV08, ECO:0000269|PubMed:30111894,
CC       ECO:0000269|PubMed:34620855, ECO:0000269|PubMed:38537643,
CC       ECO:0000269|PubMed:39423811}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Exonucleolytic cleavage in the 5'- to 3'-direction to yield
CC         nucleoside 3'-phosphates.; EC=3.1.16.1;
CC         Evidence={ECO:0000269|PubMed:30111894, ECO:0000269|PubMed:34620855,
CC         ECO:0000269|PubMed:38537643};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 5'-end 5'-dephospho-ribonucleotidyl-ribonucleotide-RNA + H2O
CC         = a ribonucleoside 3'-phosphate + a 5'-end dephospho-ribonucleoside-
CC         RNA + H(+); Xref=Rhea:RHEA:81375, Rhea:RHEA-COMP:13936, Rhea:RHEA-
CC         COMP:19670, ChEBI:CHEBI:13197, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:138284, ChEBI:CHEBI:231871;
CC         Evidence={ECO:0000269|PubMed:34620855};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:81376;
CC         Evidence={ECO:0000305|PubMed:34620855};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a ribonucleoside 3'-phosphate-2'-3'-cyclophospho-GMP + H2O = a
CC         ribonucleoside 3'-phosphate + 2',3'-cyclophospho-GMP + H(+);
CC         Xref=Rhea:RHEA:81319, ChEBI:CHEBI:13197, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:60837, ChEBI:CHEBI:231870;
CC         Evidence={ECO:0000250|UniProtKB:Q8IV08};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:81320;
CC         Evidence={ECO:0000250|UniProtKB:Q8IV08};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 5'-end 5'-dephospho-2'-deoxyribonucleotidyl-2'-
CC         deoxyribonucleotide in single-stranded DNA + H2O = a 5'-end
CC         dephospho-2'-deoxyribonucleoside in single-stranded DNA + a 2'-
CC         deoxyribonucleoside 3'-phosphate + H(+); Xref=Rhea:RHEA:81379,
CC         Rhea:RHEA-COMP:19701, Rhea:RHEA-COMP:19702, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:131705, ChEBI:CHEBI:136416,
CC         ChEBI:CHEBI:231873; Evidence={ECO:0000269|PubMed:30111894,
CC         ECO:0000269|PubMed:38537643};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:81380;
CC         Evidence={ECO:0000305|PubMed:30111894, ECO:0000305|PubMed:38537643};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 5'-end 5'-phospho-2'-deoxyribonucleotide in single-stranded
CC         DNA + H2O = a 5'-end 5'-dephospho-2'-deoxyribonucleotide in single-
CC         stranded DNA + phosphate; Xref=Rhea:RHEA:82335, Rhea:RHEA-COMP:19868,
CC         Rhea:RHEA-COMP:19869, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:136412, ChEBI:CHEBI:136416;
CC         Evidence={ECO:0000269|PubMed:38537643};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:82336;
CC         Evidence={ECO:0000305|PubMed:38537643};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3-lyso-sn-glycero-1-phospho-(3'-acyl-1'-sn-glycerol) + a 1-
CC         acyl-sn-glycerol = a 3-acyl-sn-glycero-1-phospho-(3'-acyl-1'-sn-
CC         glycerol) + glycerol; Xref=Rhea:RHEA:82563, ChEBI:CHEBI:17754,
CC         ChEBI:CHEBI:64683, ChEBI:CHEBI:77717, ChEBI:CHEBI:232393;
CC         Evidence={ECO:0000250|UniProtKB:Q8IV08};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:82564;
CC         Evidence={ECO:0000250|UniProtKB:Q8IV08};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3-lyso-sn-glycero-1-phospho-(3'-(9Z-octadecenoyl)-1'-sn-
CC         glycerol) + 1-(9Z-octadecenoyl)-sn-glycerol = 3-(9Z-octadecenoyl)-sn-
CC         glycero-1-phospho-(3'-(9Z-octadecenoyl)-1'-sn-glycerol) + glycerol;
CC         Xref=Rhea:RHEA:82567, ChEBI:CHEBI:17754, ChEBI:CHEBI:75757,
CC         ChEBI:CHEBI:139150, ChEBI:CHEBI:232394;
CC         Evidence={ECO:0000250|UniProtKB:Q8IV08};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:82568;
CC         Evidence={ECO:0000250|UniProtKB:Q8IV08};
CC   -!- ACTIVITY REGULATION: The exonuclease activity toward ssDNA substrate is
CC       Ca(2+) and Mg(2+)-independent, but it is inhibited by Fe(2+), Cu(2+)
CC       and to a lesser extent Zn(2+) ions. {ECO:0000269|PubMed:38537643}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is about 5. {ECO:0000269|PubMed:30111894,
CC         ECO:0000269|PubMed:34620855};
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:21085684}; Single-pass type II membrane protein
CC       {ECO:0000305|PubMed:21085684}. Golgi apparatus, trans-Golgi network
CC       membrane {ECO:0000269|PubMed:21085684}; Single-pass type II membrane
CC       protein {ECO:0000305|PubMed:21085684}. Nucleus
CC       {ECO:0000269|PubMed:22102906}. Early endosome
CC       {ECO:0000305|PubMed:22102906}. Cytoplasmic vesicle, phagosome
CC       {ECO:0000269|PubMed:22102906}. Lysosome {ECO:0000250|UniProtKB:Q8IV08}.
CC       Note=Activation of microglia induces translocation of PLD4 from the
CC       nucleus to the phagosomes. {ECO:0000269|PubMed:22102906}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8BG07-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8BG07-2; Sequence=VSP_023630;
CC   -!- TISSUE SPECIFICITY: Enriched in the white matter of early postnatal
CC       brains, as well as in splenic marginal zone cells (PubMed:21085684).
CC       Highly expressed in dendritic cells (DCs) and other myeloid cells, with
CC       lower expression in B cell (PubMed:30111894).
CC       {ECO:0000269|PubMed:21085684, ECO:0000269|PubMed:30111894}.
CC   -!- DEVELOPMENTAL STAGE: First detected in cerebellum at postnatal day 0
CC       (P0), increased with age and peaked at P7, and then rapidly decreased
CC       to adult levels by P21. {ECO:0000269|PubMed:21085684}.
CC   -!- INDUCTION: Up-regulated by lipopolysaccharide (LPS) stimulation in
CC       microglia (PubMed:22102906). Increased expression in activated
CC       microglia and in the demyelinating lesions of adult brain
CC       (PubMed:22102906). {ECO:0000269|PubMed:22102906}.
CC   -!- PTM: Highly N-glycosylated. {ECO:0000269|PubMed:21085684,
CC       ECO:0000269|PubMed:22102906}.
CC   -!- DISRUPTION PHENOTYPE: Deficient mice exhibit a phenotype of chronic
CC       activation of the immune system, with splenomegaly marked by elevated
CC       levels of IFNG (PubMed:30111894). PDL3 and PLD4 double-deficient mice
CC       develop spontaneous lethal hemophagocytic lymphohistiocytosis with
CC       substantial liver pathology and die at 2 to 3 weeks of age. This
CC       phenotype could be prevented by expression of a single allele of either
CC       PDL3 or PLD4. {ECO:0000269|PubMed:30111894,
CC       ECO:0000269|PubMed:34620855}.
CC   -!- SIMILARITY: Belongs to the phospholipase D family. {ECO:0000305}.
CC   -!- CAUTION: Exhibits no phospholipase activity, despite two HKD motifs.
CC       {ECO:0000269|PubMed:30111894}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC32379.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK045459; BAC32379.1; ALT_FRAME; mRNA.
DR   EMBL; AK079549; BAC37681.1; -; mRNA.
DR   EMBL; AK079878; BAC37771.1; -; mRNA.
DR   EMBL; AK151551; BAE30496.1; -; mRNA.
DR   EMBL; AK170362; BAE41745.1; -; mRNA.
DR   EMBL; BC058565; AAH58565.1; -; mRNA.
DR   CCDS; CCDS26195.1; -. [Q8BG07-1]
DR   RefSeq; NP_849242.1; NM_178911.4. [Q8BG07-1]
DR   AlphaFoldDB; Q8BG07; -.
DR   SMR; Q8BG07; -.
DR   BioGRID; 222698; 2.
DR   FunCoup; Q8BG07; 332.
DR   STRING; 10090.ENSMUSP00000067002; -.
DR   GlyConnect; 2584; 4 N-Linked glycans (3 sites).
DR   GlyCosmos; Q8BG07; 8 sites, 4 glycans.
DR   GlyGen; Q8BG07; 8 sites, 6 N-linked glycans (5 sites).
DR   iPTMnet; Q8BG07; -.
DR   PhosphoSitePlus; Q8BG07; -.
DR   jPOST; Q8BG07; -.
DR   PaxDb; 10090-ENSMUSP00000067002; -.
DR   PeptideAtlas; Q8BG07; -.
DR   ProteomicsDB; 289757; -. [Q8BG07-1]
DR   ProteomicsDB; 289758; -. [Q8BG07-2]
DR   Antibodypedia; 28277; 179 antibodies from 26 providers.
DR   Ensembl; ENSMUST00000063888.5; ENSMUSP00000067002.4; ENSMUSG00000052160.8. [Q8BG07-1]
DR   GeneID; 104759; -.
DR   KEGG; mmu:104759; -.
DR   UCSC; uc007pfc.1; mouse. [Q8BG07-1]
DR   UCSC; uc007pfd.1; mouse. [Q8BG07-2]
DR   AGR; MGI:2144765; -.
DR   CTD; 122618; -.
DR   MGI; MGI:2144765; Pld4.
DR   VEuPathDB; HostDB:ENSMUSG00000052160; -.
DR   eggNOG; KOG3603; Eukaryota.
DR   GeneTree; ENSGT00950000183059; -.
DR   HOGENOM; CLU_027021_0_0_1; -.
DR   InParanoid; Q8BG07; -.
DR   OMA; GYIIPVF; -.
DR   OrthoDB; 1923775at2759; -.
DR   PhylomeDB; Q8BG07; -.
DR   TreeFam; TF313378; -.
DR   Reactome; R-MMU-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-MMU-2029485; Role of phospholipids in phagocytosis.
DR   BioGRID-ORCS; 104759; 5 hits in 81 CRISPR screens.
DR   ChiTaRS; Pld4; mouse.
DR   PRO; PR:Q8BG07; -.
DR   Proteomes; UP000000589; Chromosome 12.
DR   RNAct; Q8BG07; protein.
DR   Bgee; ENSMUSG00000052160; Expressed in spleen and 68 other cell types or tissues.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:MGI.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0045335; C:phagocytic vesicle; IDA:UniProtKB.
DR   GO; GO:0032588; C:trans-Golgi network membrane; IDA:UniProtKB.
DR   GO; GO:0004630; F:phospholipase D activity; TAS:Reactome.
DR   GO; GO:0045145; F:single-stranded DNA 5'-3' DNA exonuclease activity; IMP:UniProtKB.
DR   GO; GO:0051649; P:establishment of localization in cell; IMP:MGI.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:MGI.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006629; P:lipid metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0006909; P:phagocytosis; IMP:MGI.
DR   GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; IMP:UniProtKB.
DR   FunFam; 3.30.870.10:FF:000013; phospholipase D3 isoform X1; 1.
DR   FunFam; 3.30.870.10:FF:000019; phospholipase D3 isoform X1; 1.
DR   Gene3D; 3.30.870.10; Endonuclease Chain A; 2.
DR   InterPro; IPR050874; Diverse_PLD-related.
DR   InterPro; IPR032803; PLDc_3.
DR   InterPro; IPR001736; PLipase_D/transphosphatidylase.
DR   PANTHER; PTHR10185:SF8; 5'-3' EXONUCLEASE PLD4; 1.
DR   PANTHER; PTHR10185; PHOSPHOLIPASE D - RELATED; 1.
DR   Pfam; PF00614; PLDc; 1.
DR   Pfam; PF13918; PLDc_3; 1.
DR   SMART; SM00155; PLDc; 2.
DR   SUPFAM; SSF56024; Phospholipase D/nuclease; 2.
DR   PROSITE; PS50035; PLD; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cytoplasmic vesicle; Disulfide bond;
KW   Endoplasmic reticulum; Endosome; Exonuclease; Glycoprotein;
KW   Golgi apparatus; Hydrolase; Immunity; Inflammatory response;
KW   Innate immunity; Lipid metabolism; Lysosome; Membrane; Nuclease; Nucleus;
KW   Phospholipid metabolism; Reference proteome; Repeat; Signal-anchor;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..503
FT                   /note="5'-3' exonuclease PLD4"
FT                   /id="PRO_0000280334"
FT   TOPO_DOM        1..36
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:21085684"
FT   TRANSMEM        37..57
FT                   /note="Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000305"
FT   TOPO_DOM        58..503
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305|PubMed:21085684"
FT   DOMAIN          207..234
FT                   /note="PLD phosphodiesterase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   DOMAIN          421..447
FT                   /note="PLD phosphodiesterase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        212
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        212
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        214
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        219
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        426
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        426
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000250|UniProtKB:Q96BZ4"
FT   ACT_SITE        428
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   ACT_SITE        433
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00153"
FT   CARBOHYD        89
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        148
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        169
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        247
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        279
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        415
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        425
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   CARBOHYD        442
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   DISULFID        92..248
FT                   /evidence="ECO:0000250|UniProtKB:Q96BZ4"
FT   DISULFID        377..501
FT                   /evidence="ECO:0000250|UniProtKB:Q96BZ4"
FT   VAR_SEQ         1..9
FT                   /note="MDKKKEHPE -> M (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16141072"
FT                   /id="VSP_023630"
FT   CONFLICT        223
FT                   /note="I -> V (in Ref. 2; AAH58565)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        294
FT                   /note="F -> L (in Ref. 1; BAE41745)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        450
FT                   /note="H -> Y (in Ref. 1; BAE41745)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        452
FT                   /note="A -> G (in Ref. 1; BAC32379)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        455
FT                   /note="G -> V (in Ref. 1; BAC32379)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        483
FT                   /note="D -> G (in Ref. 1; BAC32379)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        489
FT                   /note="A -> G (in Ref. 1; BAC32379)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   503 AA;  56154 MW;  D72EB7DEBAC9598F CRC64;
     MDKKKEHPEM RIPLQTAVEV SDWPCSTSHD PHSGLGMVLG MLAVLGLSSV TLILFLWQGA
     TSFTSHRMFP EEVPSWSWET LKGDAEQQNN SCQLILVESI PEDLPFAAGS PTAQPLAQAW
     LQLLDTARES VHIASYYWSL TGLDIGVNDS SSRQGEALLQ KFQQLLLRNI SVVVATHSPT
     LAKTSTDLQV LAAHGAQIRQ VPMKQLTGGV LHSKFWVVDG RHIYVGSANM DWRSLTQVKE
     LGAIIYNCSN LAQDLEKTFQ TYWVLGTPQA VLPKTWPRNF SSHINRFHPL RGPFDGVPTT
     AYFSASPPSL CPHGRTRDLD AVLGVMEGAR QFIYVSVMEY FPTTRFTHHA RYWPVLDNAL
     RAAALNKGVH VRLLVSCWFN TDPTMFAYLR SLQAFSNPSA GISVDVKVFI VPVGNHSNIP
     FSRVNHSKFM VTDKTAYVGT SNWSEDYFSH TAGVGLIVSQ KTPRAQPGAT TVQEQLRQLF
     ERDWSSHYAM DLDRQVPSQD CVW
//
